Search

The potential problems of DNA extraction from formalin‐fixed paraffin‐embedded (FFPE) tissue samples and amplification efficiency of Human papilloma virus (HPV) may occur in the molecular studies of head and neck squamous carcinoma (HNSCC). The aim of this study was to compare HPV detection rate in FFPE tissues of oral, oropharyngeal, hypopharyngeal, and laryngeal cancers using two silica‐based extraction kits and three amplification methods. A total of 50 FFPE specimens from HNSCC tissues were analyzed. The quality and quantity of the extracted DNA were tested by spectrophotometry. HPV DNA was detected using a single polymerase chain reaction (PCR), a nested PCR, and a Real‐time PCR kit. Statistically significantly higher DNA quality and quantity was observed using the QIAamp DNA FFPE Tissue Kit than when using the QIAamp DNA Mini Kit. There was not HPV amplification in any of the 50 FFPE samples using the single PCR and Real‐time PCR kits, whereas HPV DNA was detected in 22% of samples using nested PCR. Comparing results of the three different methods showed that HPV DNA was detected only with nested PCR. The results presented imply that nested PCR is the most appropriate method for the detection of HPV DNA in FFPE samples, along with adequate DNA extraction methods. [ABSTRACT FROM AUTHOR]

Head and neck cancers (HNC) are a heterogeneous group of diseases. Histopathological, these are head and neck squamous cell carcinoma (HNSCC) epithelium of the skin, mucosa of the upper aerodigestive tract, pharynx and larynx. HNSCC is the fifth leading cause of cancer worldwide. The most important risk factors are alcohol and smoking. In the recent years, the studies have been conducted in order to prove the role of HPV in HNSCC carcinogenesis. The prevalence of HPV in HNSCC is 30%. HPV is often detected in biological materials of males. People with HPV positive HNSCC respond better to treatment and have a better treatment outcome than patients with no proven HPV. In the future, HPV should be the marker that will influence the choice of therapy in patients with HNSCC, but also the factor that will indicate the outcome of this malignancy in the human population. [ABSTRACT FROM AUTHOR]